6月24日 - ** Taysha Gene Therapies（TSHA.O）股价在盘后交易中下跌8.5%，至6.35美元，该公司正计划进行股权融资
** TSHA (link) 启动2亿美元募资计划，包括股票和预先注资的认股权证
** 杰富瑞、高盛、派珀桑德勒和坎托菲茨杰拉德担任联合簿记管理人
** 该公司正在研发的领先临床项目TSHA-102用于治疗雷特综合征，这是一种罕见的神经发育障碍，目前尚无获批的疾病修饰疗法
** TSHA股价已连续五个交易日上涨，周三收盘上涨1.2%，报6.95美元；过去三个月股价累计上涨51%，年初至今上涨26%
** 总部位于得克萨斯州达拉斯的TSHA公司流通股约为2.874亿股，市值约为20亿美元
** 据LSEG数据显示，全部13位分析师均对该股持看涨态度，目标价中位数为12美元
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.